Prof. Dr Mohamed-Dahmani Fathallah
Total Page:16
File Type:pdf, Size:1020Kb
Prof. Dr Mohamed-Dahmani Fathallah 1 - Profile Professor of Biotechnology, Higher Education Manager, Certified Innovation Strategist & Expert in Biotech Management with: 30 years of International experience In Academia : Teaching, Scientific Research & Development ,Training, Supervision and higher education strategy and management (Curricula design, Department chairing, Deanship) 25 years of Biopharmaceutical products & Bio Services Development, Production, Regulations and Market Analysis. 20 years of International Biotech high Management, Transfer of technology, Strategy Setting, Consultancy, Business Assessment. 2 - Personal Data Nationality : Tunisian City of Residence: Manama, Bahrain Date of Birth : 03-02-1957 Contact Number: (973) 17239621 Place of Birth : Kairouan-Tunisia E-Mail address : [email protected] [email protected] 3.-Current position: Arabian Gulf University, Manama Bahrain Since September 2009: Professor of Biotechnology. Dean College of Graduate Studies. Chairman of the Biotechnology PhD Program. Chairman of the College of Graduate Studies Council. Head of the College of Graduate Studies Scientific Research Committee. Head of AGU Promotion Committee. Editor in Chief: Arab Gulf Journal of Scientific Research. Member of the Arabian Gulf University Strategy Steering Committee Other Activities: UN expert in Science, Technologies & Innovation Senior Technology Transfer, International Consultant. Member of the National Board for Scientific Research at 1 Bahrain Ministry of Education Page Member of the National Board for High Education accreditation at Bahrain Ministry of Education. Vice president of the Clinical Trials Committee at the Bahraini National Health Regulations Authority. “NAHRA” Member of the Jury of King Faisal International Prize for Sciences Member of the International Board of the Arab-German Academy of Sciences Member of the Al Fiqh Al Islamy International Academy-Jeddah-KSA President and Founder Harvard Alumni in Tunisia. Co-Founder Arab Policy Institute “Tunisian Think Tank” Tunisia. Headed the Al Jawhara Medical Research Institute Strategic Committee. Member of King Abdullah Medical City project steering Committee. Co-Founder and Overseas’ President of MEGA , the Middle East Geneticists Association, USA 4 - Employment History: Dates: September 2009 to date: Arabian Gulf University, Manama, Bahrain Dean College of Graduates studies Professor and Chairman of the Biotechnology Program King Fahd Chair of Medical Biotechnology Major achievements: managerial & Academic MANAGERIAL: Contribution to the development of two of the university quinquennial strategic plans. Restructuring of the College of graduate studies through the development and implementation of a new organization that improved administrative functions. Development of new policies and Streamlining with the university strategic objectives. Contributed to the university, institutional accreditation from NCAAA. Development of a new strategy for scientific research that yielded a 200% increase of international scientific publications and 300 % of IP production Introduction of novel education technologies at the college class room (Black board, moodles, blended learning) Improvement the college international visibility through the organization of international scientific events[conferences, workshops, seminars, scientific journal “ The Arabian Gulf Journal for Scientific Research) Increase of the international collaboration with world-class universities and research organizations. 2 Page ACADEMIC Review and revision of all the programs curricula (17) according to international criteria. Development and Launching of a PhD program in Biotechnology [Health & Environment] Development and Launching of a PhD program in Innovation Management. Development of a graduate level program in Bioinformatics. Production of the first genetically modified transgenic animal (Mouse) in an Arab research and education institution by my research group at AGU. (Patent Pending) Development of monoclonal antibodies for cancer treatment engineered to fit the genetic background of patients by my research group at AGU. (Patent Pending). Development by genetic engineering of a novel biological agent for the treatment of inflammation by my research group at AGU. (Patent Pending) Development of generic improved form of the biodrugs : Interferon Gamma and Interferon alpha by my research group at AGU. (Patent Pending) Trained/Supervised 9 PhD and 15 Master students Dates: September 2008-August 2009: Sabbatical year King Saud University, Ryadh, Saudi Arabia Visiting Professor /College of Pharmacy Senior Advisor Strategy, KSU Transfer of Technology Office and Riyadh Techno Valley/ KSU President Office Dates: May 2004-August 2008: JeddahBiocity Inc (A biotechnology Holding Group) Location: Jeddah,KSA Position: Group Chief Scientific Officer CEO RethAb Branch: General Manager JBC is a leading biotech holding company. Its business is to screen for technically advanced biotech businesses, transfer of Technology, invest in existing companies and/or create and foster biotech companies, offer them to the market for equity investment and collect premium on the benefit. The company annual turnover was around 200 million SR Major achievements: Biotech Business Acquisition, Joint venture & Technology Transfer I have selected, evaluated and transferred the technology from “GeneWay” a San Diego, California-US biotech company in which JBC invested 4 M US $. I have developed two other biotech companies. Namely “Arabio”[100M $ investment] which is the first vaccine manufacturing company in the Middle East and BioScan [75 M$ SR Investment] the first private company specialized in advanced medical imaging for early diagnostic of cancer in KSA. JBC collected a substantial premium upon inviting equity investors in these two companies I have carried out the feasibility studies and promotion of two science parks projects [Jeddah & Medina]. I have founded “RethAb” a JBC startup company specialized in the development of Antibodies.[18 M$ SR investment] and acted as its CEO 3 Page Dates July 93-April 2004 Institute Pasteur/University Tunis Al Manar/ Location: Tunis Position: Senior Scientist/Group Leader Professor of Molecular Biotechnology The Pasteur Institute is a semi public/Private centennial institution affiliated with to the University of Tunis AL Manar. Its main business is to provide health care services mainly through vaccines manufacturing and supply and to carry out health products & services research and development along with academic training. Major Achievements: academic, scientific research & management Teaching &Training Taught Molecular Biology, Molecular Genetics, Immunology, Biotechnology, and Cell Biology to Graduates Life sciences and biomedical sciences students. Trained/Supervised 18 PhD and 35 Master students 2 medical doctors’ thesis and graduated 15 Engineers in Biotechnology& Medical Sciences. Research &Development & Technology Transfer Development/invention of five health care products & filled for five international discovery patents USA & Europe: 1. Two clones and a full process for the production of recombinant human interferon alpha in Pichia pastoris: EPO [European Patent Organization] 2. A strategy to produce soluble recombinant human interferon alpha in E.Coli: USPTO [United State Patent Trade Organization] 3. Selegrin: A novel Chimeric, genetically engineered adhesion molecule with anti-inflammatory potential; [EPO] 4. A novel antibody to the pro inflammatory leukocyte adhesion molecule CR3: [USPTO] 5. Method for preparing recombinant mycobacterial polypeptides in yeast and their use in diagnostic of mycobacterial related diseases: [USPTO] Established strategic business alliances with world top pharmaceutical companies and transferred the technology for an anti-inflammatory monoclonal antibody [Serono International, Switzerland], and a serology kit for the diagnostic of tuberculosis [ Biorad International USA] Raised and managed up to 2.5M US $ of grants for biotech-products development. Established Tunisia first national service of DNA-based paternity testing and realized a CAGR of 46%. Transferred the technology to four new companies. Co-Founded “Cylyx” a biotech startup company in the biopharmaceutical Field. Built worldwide collaborative network for biotech development. 4 Page Dates: 1985 - 1993 Harvard University/Mass General Hospital Location: Boston -USA Position: April 85-June 1989 Postdoctoral fellow Children Hospital/Harvard Medical School July1989-September 1993: Senior Scientist: Massachusetts General Hospital/Harvard Medical school MGH is a Harvard University Medical, Research and training center. My assignment was a research & development scientist at the Navy Yard research facility that was dedicated to the development of startup companies specialized in medical biotechnology. Major Achievements: academic, scientific research & management Raised and managed up to 4 M US $ of grants for biotech-products development Development of new health care products and procedures for which I was granted international discovery patents Founded “MEGA” The middle East Geneticists Association of America Trained and supervised students & staff. 4-Transfer of technology Activity: From 1998 to date: Strategic and Technology transfer advisor to several international Pharmaceutical companies.[PSI, SAJA, MEDIS, WestPharma,Biocare,UniMed…] Strategic & Technology transfer advisor and member